In conclusion, a combination of a 35-gene mutation profile and RT dosimetry identified mutations in FSIP2 and SYNE1 as well as lung V30 and clinical nodal staging as potential predictors for developing a prediction model for clinical outcomes of patients with ESCC treated with definitive CCRT. This evidence concerns the gene FSIP2 and esophageal squamous cell carcinoma.